Device Therapy Targeting the Neurohormonal Pathway in Heart Failure Patients 

Barostim is a novel device therapy that works with guideline-directed medical therapy and targets the neurohormonal pathways responsible for heart failure progression and symptoms. At our THT 2025 symposium, an experienced faculty discussed the unmet needs with drug and device therapies in patients with Class II/III HFrEF, patient selection, and real world outcomes and strategies for incorporating Barostim into a comprehensive heart failure program. Watch the presentations to learn more.

Patient Selection Protocols & Care Pathways within an Advanced HF Program

Richa Gupta, MD

Drug and Device Therapies to Target the Neurohormonal Cascade

Rajeev Mohan, MD

Real-world Results with Barostim within a Multi-disciplinary HF Program

Patrick McCann, MD

Dr. Richa Gupta, Dr. Rajeev Mohan, and Dr. Patrick McCann are paid consultants of CVRx.